Published online before print August 31, 2006, doi: 10.1161/01.RES.0000244014.19589.8e
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 25, 2006
Revised on August 9, 2006
Accepted on August 23, 2006
Tissue-Specific Induction of Intestinal ABCA1 Expression With a Liver X ReceptorAgonist Raises Plasma HDL Cholesterol Levels
Liam R. Brunham ;
From the Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, Department of Medical Genetics (L.R.B., T.D.P., M.R.H.), University of British Columbia, Vancouver, BC, Canada; Center for Liver, Digestive, and Metabolic Diseases, Laboratory of Pediatrics (J.K.K., F.K.), University Medical Center, Groningen, The Netherlands; and the Department of Pathology (J.S.P.), Wake Forest University School of Medicine, Winston-Salem, NC.
* To whom correspondence should be addressed. E-mail: mrh{at}cmmt.ubc.ca.
ABCA1 controls the rate-limiting step in HDL particle formation and is therefore an attractive molecular target for raising HDL levels and protecting against atherosclerosis. Intestinal ABCA1 significantly and independently contributes to plasma HDL cholesterol levels in mice, suggesting that induction of intestinal ABCA1 expression may raise plasma HDL cholesterol levels. We evaluated the ability of a synthetic Liver X Receptor (LXR) agonist, GW3965, to raise plasma HDL cholesterol levels in control mice and mice with liver- or intestinal-specific deletion of the Abca1 gene. Oral treatment with GW3965 increased the expression of ABCA1 by 
6-fold (P=0.004) as well as other LXR target genes in the intestines of mice, with no change in the hepatic expression of these genes. This resulted in a significant 48% elevation of plasma HDL cholesterol levels in wild-type mice (P<0.01) with no change in plasma triglycerides. A similar increase in HDL cholesterol was observed in mice lacking hepatic ABCA1, indicating that the increase in plasma HDL cholesterol was independent of hepatic ABCA1. This effect was completely abrogated in mice lacking intestinal ABCA1. These data indicate that intestinal ABCA1 may be an attractive therapeutic target for raising HDL levels while avoiding the hepatic lipogenesis and hypertriglyceridemia typical of systemic LXR activation.
Key words: atherosclerosis • high-density lipoproteins • lipids • lipoproteins • nuclear receptors
This article has been cited by other articles:
 |
|
 |
|
  J. Iqbal and M. M. Hussain Intestinal lipid absorption Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1183 - E1194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kratzer, M. Buchebner, T. Pfeifer, T. M. Becker, G. Uray, M. Miyazaki, S. Miyazaki-Anzai, B. Ebner, P. G. Chandak, R. S. Kadam, et al. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia J. Lipid Res., February 1, 2009; 50(2): 312 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Field, K. Watt, and S. N. Mathur Origins of intestinal ABCA1-mediated HDL-cholesterol J. Lipid Res., December 1, 2008; 49(12): 2605 - 2619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Colin, E. Bourguignon, A.-B. Boullay, J.-J. Tousaint, S. Huet, F. Caira, B. Staels, S. Lestavel, J.-M. A. Lobaccaro, and P. Delerive Intestine-Specific Regulation of PPAR{alpha} Gene Transcription by Liver X Receptors Endocrinology, October 1, 2008; 149(10): 5128 - 5135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Tang, Y. Ma, L. Jia, Y. A. Ioannou, J. P. Davies, and L. Yu Niemann-Pick C1-Like 1 Is Required for an LXR Agonist to Raise Plasma HDL Cholesterol in Mice Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): 448 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yvan-Charvet, T. A. Pagler, N. Wang, T. Senokuchi, M. Brundert, H. Li, F. Rinninger, and A. R. Tall SR-BI inhibits ABCG1-stimulated net cholesterol efflux from cells to plasma HDL J. Lipid Res., January 1, 2008; 49(1): 107 - 114. [Abstract] [Full Text] [PDF]
|
|